

Corporate News

April 25, 2017

MagForce AG to host Symposium for Focal Therapy in Glioblastoma at WFNOS 2017 Meeting

Berlin, Germany, and Nevada, USA, April 25, 2017 - MagForce AG (Frankfurt, Scale, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, is pleased to announce that it will host a Scientific Symposium titled “Focal Therapy in Glioblastoma - Current Status / What’s New?” at the 5th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies (WFNOS). Sponsored by the European Association of Neuro-Oncology (EANO), the WFNOS is held from May 4-7, 2017, in Zurich, Switzerland.

Moderated by Prof. Dr. Michael Weller, Chairman of the Department of Neurology at the University Hospital Zurich and President of EANO and WFNOS 2017, the one hour lunch symposium will be held Saturday, May 6 from 12:15 - 1:15 p.m. CEST in the Kongresssaal of the Kongresshaus Zurich and will feature three key note speeches: Besides an introduction of the current state of the art for glioma treatment by Prof. Weller, Prof. Michael Vogelbaum, MD/PhD, Chair for Neuro-Oncology and Neurosurgery, Cleveland Clinic, will present a latest update on focal therapy in gliomas and Prof. Walter Stummer, MD, Director of the Department of Neurosurgery at the University Hospital Münster, will talk about new aspects of thermotherapy in brain tumors.

The symposium details are as follows:

Title: “Focal Therapy in Glioblastoma - Current Status / What’s New?”

Date: Saturday, May 6, 2017

Time: 12:15 - 1:15 p.m. CEST

Location: Kongresssaal at Kongresshaus Zurich

Speakers: **Prof Michael Weller, MD (Chair/Moderation)**

University Hospital Zurich

Topic I *Introduction, Current State of the Art for Glioma treatment*

Prof Michael Vogelbaum, MD/PhD

NeuroOncology Center, Cleveland Clinic

Topic I *Focal Therapy in Gliomas – Latest Update*

Prof Walter Stummer, MD

University Hospital Münster

Topic I *New Aspects of Thermotherapy in Brain Tumors – NanoTherm® Therapy*

Press Release

MagForce AG • Max-Planck-Straße 3 • 12489 Berlin • Germany • www.magforce.com

For further information:
Barbara von Frankenberg
VP Communications
& Investor Relations

bfrankenberg@magforce.com
T +49-30-308380-77
F +49-30-308380-99
M +49 173-2792768

In addition, MagForce will be represented at WFNOS 2017 with a booth and will be available for questions regarding its NanoTherm® therapy for the treatment of glioblastoma and other brain tumors.

Focal Therapy is an important option in the treatment of glioblastoma. These tumors are the most common and most aggressive type of tumor found in the brain. In Europe, around 13,000 glioblastoma cases are diagnosed each year. Prognosis for glioma patients is still dim as often times, even after the most successful surgery, residual microscopic tumor remains and usually regrows in direct vicinity of the original resection cavity. For more local control of remaining tumour infiltration, the concept of thermotherapy for tumor ablation and as a radiosensitiser in glioma therapy could be very promising.

For more information on the WFNOS 2017 Meeting programme, please click [here](#).

About WFNOS 2017 Meeting

Hosted by the European Association of Neuro-Oncology (EANO), the 5th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies (WFNOS), held in Zurich from May 4-7, 2017, invites those involved in neuro-oncology to join this outstanding event for Neuro-Oncology worldwide. Owing to joint efforts of EANO, the US Society for Neuro-Oncology (SNO), the Asian Society for Neuro-Oncology (ASNO) and an increasing number of National Neuro-Oncology societies, WFNOS has become an active umbrella organization seeking to promote Neuro-Oncology in all aspects of care and research, and everywhere across the globe. Thus, WFNOS 2017 will provide an opportunity to share up-to-date advances in basic science, translational and clinical research in a multidisciplinary setting. The four day programme will feature among others, clinical and research updates, key note lectures and poster presentations as well as a symposium on the current status and future of focal therapy in glioblastoma.

About MagForce AG and MagForce USA, Inc.

MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm® therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. Mithril Capital Management, a growth-stage technology fund founded by Ajay Royan and Peter Thiel, along with MagForce AG, are investors and strategic partners in MagForce USA, Inc.

NanoTherm®, NanoPlan®, and NanoActivator® are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.

Press Release

MagForce AG • Max-Planck-Straße 3 • 12489 Berlin • Germany • www.magforce.com

For further information:
Barbara von Frankenberg
VP Communications
& Investor Relations

bfrankenberg@magforce.com
T +49-30-308380-77
F +49-30-308380-99
M +49 173-2792768

For more information, please visit: www.magforce.com.

Get to know our Technology: [video \(You Tube\)](#)

Stay informed and subscribe to our [mailing list](#).

Disclaimer

This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.

Press Release

MagForce AG • Max-Planck-Straße 3 • 12489 Berlin • Germany • www.magforce.com

For further information:
Barbara von Frankenberg
VP Communications
& Investor Relations

bfrankenberg@magforce.com
T +49-30-308380-77
F +49-30-308380-99
M +49 173-2792768